Is a 99.4% result from Medutest comparable to 96.8% from PeptideMeter?

Setup, so nobody has to ask: 99.4% · Medutest · 96.8% · PeptideMeter.

Both of these get recommended confidently by different people, which suggests neither is obviously right.

My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.

What is the actual trade-off, and does it matter at the scale I am working at?

99.4 and 96.8 are 2.6 percentage points apart, which sounds small until you restate it as impurity. Medutest is leaving 0.6 per cent of the detected area unassigned and PeptideMeter 3.2 per cent — a factor of 5.33 between them. The impurity fraction is the quantity that moves when a method changes, and it is the one worth arguing about; the headline is just its complement. Comparable means same column chemistry, same gradient slope, same detection wavelength, same integration convention. Until you have those four from both laboratories, 99.4 and 96.8 are two measurements of slightly different quantities that happen to share a unit.

More usefully, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Reconciling gross mass to label claim

Specifically, gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

To be exact about it, mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

If you are ranking vendors, specify a method and have all samples tested at the same place.

In practice, identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

The method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

edited 25 Apr 2026 by tabular_nums — corrected a unit error in the worked example

The relevant detail is that understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.